Agilent Technologies Inc (NYSE:A) – Research analysts at Svb Leerink dropped their Q3 2019 earnings per share (EPS) estimates for Agilent Technologies in a report issued on Wednesday, May 15th. Svb Leerink analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.72 for the quarter, down from their previous forecast of $0.74. Svb Leerink also issued estimates for Agilent Technologies’ Q1 2020 earnings at $0.82 EPS and FY2021 earnings at $3.64 EPS.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Tuesday, May 14th. The medical research company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.01). The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.65 earnings per share.
NYSE:A opened at $69.30 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.39 and a quick ratio of 2.79. The stock has a market capitalization of $23.45 billion, a price-to-earnings ratio of 24.84, a PEG ratio of 2.05 and a beta of 1.33. Agilent Technologies has a 1-year low of $60.42 and a 1-year high of $82.27.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its stake in shares of Agilent Technologies by 3.9% in the fourth quarter. Parallel Advisors LLC now owns 4,002 shares of the medical research company’s stock valued at $269,000 after purchasing an additional 149 shares during the period. Fruth Investment Management increased its stake in shares of Agilent Technologies by 0.3% in the fourth quarter. Fruth Investment Management now owns 45,351 shares of the medical research company’s stock valued at $3,059,000 after purchasing an additional 150 shares during the period. BOKF NA increased its stake in shares of Agilent Technologies by 1.4% in the fourth quarter. BOKF NA now owns 11,229 shares of the medical research company’s stock valued at $757,000 after purchasing an additional 158 shares during the period. Sumitomo Life Insurance Co. increased its stake in shares of Agilent Technologies by 1.3% in the fourth quarter. Sumitomo Life Insurance Co. now owns 13,394 shares of the medical research company’s stock valued at $904,000 after purchasing an additional 178 shares during the period. Finally, Mission Wealth Management LP increased its stake in shares of Agilent Technologies by 2.1% in the fourth quarter. Mission Wealth Management LP now owns 8,629 shares of the medical research company’s stock valued at $582,000 after purchasing an additional 179 shares during the period.
In related news, CEO Michael R. Mcmullen sold 8,745 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $80.00, for a total transaction of $699,600.00. Following the sale, the chief executive officer now owns 438,939 shares in the company, valued at $35,115,120. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Mark Doak sold 16,421 shares of the stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $77.95, for a total transaction of $1,280,016.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,583 shares of company stock worth $3,855,924.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were paid a dividend of $0.164 per share. The ex-dividend date of this dividend was Monday, April 1st. This represents a $0.66 annualized dividend and a yield of 0.95%. Agilent Technologies’s dividend payout ratio (DPR) is 23.66%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: Why investors pay attention to retained earnings
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.